 |
 |
 |
|
Long-term Follow-up of Patients Treated With Sofosbuvir in the Phase 3 Studies FISSION, POSITRON, FUSION, and NEUTRINO
|
|
|
Reported by Jules Levin
EASL 2014 April 9-13 London, UK
Wendy Cheng,1 Stephen Shafran,2 Kimberly Beavers,3 Hongmei Mo,4 John McNally,4 Diana M. Brainard,4 William T. Symonds,4 Mario Chojkier,5 Alessandra Mangia,6 Christian Schwabe7
1Royal Perth Hospital, Perth, Western Australia, Australia; 2University of Alberta, Edmonton, Canada; 3Asheville Gastroenterology Associates, Asheville, North Carolina, USA; 4Gilead Sciences, Inc., Foster City, California, USA;
5University of California, San Diego; 6Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo, Italy; 7Auckland Clinical Studies, Auckland, New Zealand





|
|
|
 |
 |
|
|